The Tiny Tech Turning Biologics Into Simple Shots

Acquisition of Electrofi adds next-gen drug formulation and smart injection technology to Halozyme’s tech portfolio

29 Oct 2025

Halozyme Therapeutics is expanding its technology footprint with the $900mn acquisition of Electrofi, a biotech start-up whose formulation platform enables ultra-concentrated biologics to be delivered through compact injection devices.

The deal includes $750mn upfront and up to $150mn in milestone payments. It brings Halozyme a proprietary process for creating biologic formulations at 400 to 500mg/mL concentrations, around five times higher than current standards. The technology, known as Hypercon, allows drugmakers to maintain stability and injectability at higher densities, paving the way for faster, portable delivery systems.

By absorbing Electrofi’s formulation and device expertise, Halozyme is positioning itself at the intersection of biotechnology and engineering. The company said Hypercon would accelerate the development of smaller, connected self-injection systems, advancing trends in at-home treatment and digital health integration.

“Electrofi’s platform adds a new dimension to our drug delivery technology stack,” Halozyme said in a statement, describing the acquisition as an investment in “how biologics are designed, formulated, and experienced by patients.”

Analysts view the transaction as part of a wider shift toward technology-driven drug design. As biologics become more complex, pharmaceutical companies are investing in digital tools, materials science, and device innovation to improve both therapeutic performance and patient usability.

Halozyme’s move mirrors efforts across the life sciences sector to blend data, hardware, and chemistry. The acquisition signals that the future of biologic delivery lies as much in technological engineering as in molecular discovery, where advances in micro-formulation and smart devices are redefining how medicine reaches the patient.